Foley Releases 2024 Top Trends Report Examining Health Care and Life Sciences Issues
Publication unpacks fast-moving developments in uncertain regulatory landscape
Foley & Lardner LLP today published its third annual Health Care & Life Sciences Top Trends report examining business and legal issues that will impact this space in 2024 and beyond.
Several significant trends are reshaping how companies across the health care and life sciences sectors operate and what they need to do to meet the evolving needs of the industry. Artificial intelligence (AI) continues to be a major disruptor, but many of the AI technologies being adopted lack legal testing, creating regulatory gray areas.
Pharmaceutical companies may also see changes in regulatory paradigms, while the U.S. Food and Drug Administration (FDA) continues to increase requirements for cosmetics manufacturers and prioritize diversity in clinical trials.
Telemedicine companies are expecting increased regulation on social media advertising and are shifting from direct-to-consumer to third-party reimbursement models. On the provider front, established health care systems are partnering with technology startups to advance their offerings.
“Today’s complex health care and life sciences landscape is characterized by rapid and unprecedented innovation driven by technology and a relentless focus on improving patient outcomes,” said Susan Pravda, chair of Foley’s Health Care & Life Sciences Sector.
Foley’s 2024 Health Care & Life Sciences Top Trends publication unpacks these fast-moving developments and more to help businesses capitalize on opportunities and navigate potential pitfalls. Articles include:
- Health Care Litigation: Overview and Assessment of the Impact of Artificial Intelligence
- Litigation Trends: How Court Decisions Will Affect Pharmaceutical Manufacturers
- Balancing Innovation and Safety: FDA Regulation of AI in Medical Devices
- Intellectual Property Strategies for Digital Health AI Companies: Increasing Valuation and Creating Barriers for Competitors
- FDA and FTC Poised to Regulate Social Media Advertising of Drugs and Digital Health Services
- FDA Regulation of Cosmetics – The Beauty or the Beast
- Direct to Patient Telehealth Companies Are Shifting From Self-Pay to Insurance Reimbursement Models
- Diversity in Clinical Trials
- Medicare Advantage Marketing Under Pressure
- 2024 will be a Critical Year for the 340B Drug Pricing Program
- Health Care Joint Ventures are Heating Up. Here’s What Providers Need to Know
Foley’s Health Care & Life Sciences Sector is comprised of more than 200 attorneys across 25 offices worldwide with decades of collective in-house experience at health care providers and vendors, pharmaceutical and biotechnology firms, and key state and federal government agencies. Foley is primed to strategically advise health care and life sciences companies through every step of their journey and all stages of their lifecycle. With deep regulatory experience coupled with a national transaction backbone, attorneys provide forward-looking, practical solutions to clients’ most pressing business challenges.
Access the full report here.
About Foley & Lardner LLP
Foley & Lardner LLP is a preeminent law firm that stands at the nexus of the Energy, Health Care and Life Sciences, Innovative Technology, and Manufacturing Sectors. We look beyond the law to focus on the constantly evolving demands facing our clients and act as trusted business advisors to deliver creative, practical, and effective solutions. Our 1,100 lawyers across 25 offices worldwide partner on the full range of engagements from corporate counsel to intellectual property work and litigation support, providing our clients with a one-team solution to all their needs. For nearly two centuries, Foley has maintained its commitment to the highest level of innovative legal services and to the stewardship of our people, firm, clients, and the communities we serve.